Clinical relevance of circulating microRNAs as lung cancer biomarkers
Deep sequencing of circulating tumor DNA for personalized lung cancer detection and radiotherapy response monitoring
Circulating tumor cell eXplants (CDX) to advance small cell lung cancer (SCLC) research and drug development
Immunotherapy in small cell lung cancer
Using stem cell biology to design precision medicine for non-small cell lung cancer
Potential of FLASH irradiation to minimize the incidence of radio-induced damage and fibrosis to normal lung in a mouse model
Radiomics of lung cancer
From bench to bedside to beam: Hippocampal-sparing during cranial irradiation
Primary and adaptive resistance to checkpoint blockade in lung cancer
Tobacco smoke toxicant and carcinogen biomarkers and lung cancer susceptibility in smokers
Targeting PD1 and PDL1 in lung cancer treatment: Where are we now?
Beyond monotherapy: Integrating immunotherapy into current treatment regimens
Targeting K-Ras cancers
Immunomodulatory effects of radiotherapy: Magical effects of the healing beam?
Sox2 cooperates with Lkb1 loss to promote squamous cell lung cancer
Proximalization therapy for KRas mutant adenocarcinoma
Adenocarcinoma indolence and progression: Biological basis
Identification and targeting of long-term tumor-propagating cells in small cell lung cancer
Predictive biomarkers for immunotherapy in lung cancer: Opportunities and challenges
Impact of co-mutations on the immune microenvironment of KRAS-mutant lung adenocarcinoma
Oncogenic KRAS regulates asparagine synthase
Blood-based biomarkers for lung cancer: Ready for prime time?
Modeling lung cancer with CRISPR/Cas9
Intratumoral heterogeneity and EGFR-TKIs resistance
Efficacy and safety of dovitinib in pretreated advanced squamous non-small cell lung cancer with FGFR1 amplification: A single-arm, phase II study
A novel patient-derived cell line originated at the time of crizotinib resistance displays a mesenchymal phenotype
Immune profiling of malignant pleural mesothelioma by flow cytometry identifies distinct T-cell activation and exhaustion phenotypes in PD-L1 positive versus PD-L1 negative tumors
Novel epidermal growth factor receptor inhibitor accumulates in the brain and inhibits the growth of brain metastatic non-small cell lung cancer
Gold nanorod immunoassay to quantify C-Met expression in NSCLC patients selected for anti-EGFR therapy
Quantitative mass spectrometry-based proteomics identifies FRalpha and GARFT as predictive biomarkers in tissues of non-squamous NSCLC patients treated with pemetrexed
Deregulated SOX2 drives dysplasia in a novel 3D organotypic model of bronchial dysplasia
ELF3 amplification at 1q32.1 promotes SMAD4-independent tumorigenesis
Detection of a novel RET gene fusion in a non-small cell lung cancer patient using AMP chemistry
The transcription factor Slug induces diverse malignant phenotypes in models of established lung cancer and pulmonary premalignancy
Structural analysis identifies an orally active PCNA inhibitor that inhibits the growth of small cell lung cancer cells without causing significant toxicity to nonmalignant cells
Translational application of microRNA profiling for early detection of lung cancer: A comparison of sputum and blood
Targeting immunosuppressive mechanisms in KRAS mutant lung cancer
Mutational profile of non-small cell lung cancer by targeted next-generation sequencing in the Mexican population
Detection of viral induced double-stranded RNA intermediates in archival paraffin blocks
Prediction of distant recurrence-free survival in resectable lung adenocarcinoma
Strong pharmacological activity of locally administered next-generation antisense oligonucleotides (ASOs) in orthotopic lung cancer mouse models
Impact of interleukin-22 on K-ras mutant lung cancer promotion and stemness properties
Determination of real-time tumor oxygenation changes following high-dose radiotherapy in orthotopic and subcutaneous lung cancers in mice
Nonclassical activation of gli1 as a therapeutic target for squamous cell lung cancer
Validation of L-Myc as a viable therapeutic target in small cell lung cancer
E2F8 and its target genes as novel therapeutic targets for lung cancer
Rare but poor prognosis of TERT promoter mutation in non-small cell lung cancer patients
Loss of somatostatin receptor 2 expression reduces small cell lung cancer growth and alters cellular metabolism
An epigenetic switch leads to EMT memory in chronic inflammation in non-small cell lung cancer
Design of a phase 3, international multicenter, prospective, randomized, double-blind, placebo controlled study assessing the efficacy and safety of lanreotide depot 120 mg in patients with well-differentiated, advanced typical and atypical lung neuroendocrine tumors (NETs)
Heterogeneity of programmed cell death-ligand 1 expression in lung cancer
Optimized NGS panel and data analysis enable high sensitivity of detecting colon and lung cancer associated mutations from plasma
Constitution of ALK fusion variants in East Asian lung adenocarcinoma
Mutation status matters: RAS, p53, and targeting autophagy as a potential strategy in NSCLC
Unique roles for Akt isoforms in lung cancer
Whole blood FPR1 mRNA expression identifies both non-small cell and small cell lung cancer
Serum glutathione peroxidase 3 as a biomarker of postoperative relapse in patients with lung cancer*
The biological impact of e-cigarettes on airway epithelial cell transformation and gene expression
Long-term treatment with dexamethasone induces senescence and progressive loss of proliferation potential in lung adenocarcinoma cells expressing high levels of the glucocorticoid receptor
Phase I/II trial of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor, in patients with ALK+ non-small cell lung cancer (NSCLC)
Liquid biopsies could be superior to tumor biopsy to provide a molecular profile in non-small cell lung cancer (NSCLC) patients
The triptolide derivative MRx102 inhibits Wnt pathway activation and has potent anti-tumor effects in lung cancer
Gene expression classifier for prognosis of early-stage squamous cell carcinoma of the lung
A functional SNP in MRPL43 modulates lung cancer susceptibility and survival through alternative splicing of its isoforms
Prognostic nomogram for predicting survival of non-small-cell lung cancer patients*
High expression of endoplasmic reticulum oxidoreductin (ERO) 1L is associated with resistance to cisplatin
Intratumoral CCL21 and checkpoint blockade cooperatively inhibit NSCLC tumor growth in vivo to a greater extent than either monotherapy alone
Diagnostic and predictive quantitative-imaging features in lung cancer screening
Myxomavirus (MYXV) therapy for small cell lung cancer (SCLC) using patient samples and a genetically engineered SCLC mouse model
MET:GRB2 complexes define a subset of lung cancer with potential vulnerability to MET inhibition
Natural antisense transcript deregulation in non-small cell lung cancer
ART1, an extracellular ADP-ribosyltransferase, is over-expressed in non-small cell lung cancer and facilitates cancer cell survival by immune-mediated mechanisms
Routine molecular testing of resected early-stage lung adenocarcinoma with targeted next-generation sequencing demonstrates a high rate of actionable mutations
Functional lung adenocarcinoma risk SNPs identified through positional integration with human alveolar epithelial cell epigenomes
Magnetic nanocubes for selective capture of circulating tumor cells in NSCLC
Targeted nanoconjugate co-delivering siRNA and tyrosine kinase inhibitor to Kras mutant NSCLC reveals Gab1 assisted survival pathway post oncogene knockdown
miR-342–3p regulates MYC transcriptional activity via direct repression of E2F1 in human lung cancer
Loss of immunoproteasome driven by EMT is associated with immune evasion and poor prognosis in non-small cell lung cancer
NRG-LU001: A phase II trial investigating metformin as a chemo-radio-sensitizer in locally advanced non-small cell lung cancer (NSCLC)
Targeting tumor metabolism to improve radio-sensitivity in non-small cell lung cancer (NSCLC)
OCOG-ALMERA: A phase II trial investigating the ability of metformin to chemo-radio-sensitize and prevent recurrence in locally advanced (LA) non-small cell lung cancer (NSCLC)*
An integrative cross-tumors approach identifies FOSL1 as an oncogene dependency in KRAS-driven lung cancer
Intelligent forceps for solitary pulmonary nodule diagnostics*
Characterization of programmed cell death-1 ligand (PD-L1) expression in circulating tumor cells (CTCs) of lung cancer
Validation of DNA methylation marker SHOX2 and PTGER4 for detection of lung cancer in plasma
Control for stochastic sampling variation and qualitative sequencing error in next generation sequencing analysis of KRAS actionable mutations
Characteristics, oncogene dependency, and response to ponatinib of a novel transgenic mouse model of KIF5B-RET-induced lung adenocarcinoma
Mechanism of Notch and Sox2 in Kras driven lung adenocarcinoma in type II cells*
ROR1 functions as a scaffold of cavin-1 and CAV1, sustaining caveolae and RTK-mediated survival signaling in lung cancer